8-BuS-ATP derivatives as specific NTPDase1 inhibitors

Joanna Lecka, Irina Gillerman, Michel Fausther, Mabrouka Salem, Mercedes N. Munkonda, Jean Philippe Brosseau, Christine Cadot, Mireia Martín-Satué, Pedro D'Orléans-Juste, Éric Rousseau, Donald Poirier, Beat Künzli, Bilha Fischer, Jean Sévigny

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Background and Purpose Ectonucleotidases control extracellular nucleotide levels and consequently, their (patho)physiological responses. Among these enzymes, nucleoside triphosphate diphosphohydrolase-1 (NTPDase1), -2, -3 and -8 are the major ectonucleotidases responsible for nucleotide hydrolysis at the cell surface under physiological conditions, and NTPDase1 is predominantly located at the surface of vascular endothelial cells and leukocytes. Efficacious inhibitors of NTPDase1 are required to modulate responses induced by nucleotides in a number of pathological situations such as thrombosis, inflammation and cancer. Experimental Approach Here, we present the synthesis and enzymatic characterization of five 8-BuS-adenine nucleotide derivatives as potent and selective inhibitors of NTPDase1. Key Results The compounds 8-BuS-AMP, 8-BuS-ADP and 8-BuS-ATP inhibit recombinant human and mouse NTPDase1 by mixed type inhibition, predominantly competitive with Ki values <1 μM. In contrast to 8-BuS-ATP which could be hydrolyzed by other NTPDases, the other BuS derivatives were resistant to hydrolysis by either NTPDase1, -2, -3 or -8. 8-BuS-AMP and 8-BuS-ADP were the most potent and selective inhibitors of NTPDase1 expressed in human umbilical vein endothelial cells as well as in situ in human and mouse tissues. As expected, as a result of their inhibition of recombinant human NTPDase1, 8-BuS-AMP and 8-BuS-ADP impaired the ability of this enzyme to block platelet aggregation. Importantly, neither of these two inhibitors triggered platelet aggregation nor prevented ADP-induced platelet aggregation, in support of their inactivity towards P2Y1 and P2Y12 receptors. Conclusions and Implications The 8-BuS-AMP and 8-BuS-ADP have therefore potential to serve as drugs for the treatment of pathologies regulated by NTPDase1.

Original languageEnglish
Pages (from-to)179-196
Number of pages18
JournalBritish Journal of Pharmacology
Volume169
Issue number1
DOIs
StatePublished - May 2013

Keywords

  • ADP
  • ATP
  • adenine nucleotide analogue
  • ectoATPase
  • ectonucleotidase
  • inhibitors

Fingerprint

Dive into the research topics of '8-BuS-ATP derivatives as specific NTPDase1 inhibitors'. Together they form a unique fingerprint.

Cite this